Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Benefit of Vaccinating Male Against HPV-related Disease

인유두종바이러스 관련 질환의 예방을 위한 남성 대상 백신의 임상적 유용성

  • Lee, Sei Young (Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine)
  • 이세영 (중앙대학교 의과대학 이비인후과학교실)
  • Received : 2022.05.15
  • Accepted : 2022.05.24
  • Published : 2022.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

HHPV (Human Papillomavirus) is a DNA virus that can cause benign lesions, genitourinary cancer, and oropharyngeal cancer by penetrating the mucous membrane and skin. It is widely known to be transmitted mainly through sexual contact. As with many viral infections, vaccines have been developed to prevent infection with HPV. Currently, in many countries, HPV vaccines are mainly used for national immunization for women to prevent diseases that traditionally occur frequently in women, especially cervical cancer. However, since the vaccination rate is relatively low, many countries are struggling with ways to increase the vaccination rate. Meanwhile, the incidence of oropharyngeal cancer caused by HPV in men has been increasing recently. In the United States, the annual number of oropharyngeal cancers in men already exceeds the number of cervical cancers in women, so HPV infection in men has emerged as a major problem. Accordingly, interest in HPV vaccination in men has also increased, and studies on the effectiveness and necessity of vaccination of both women and men compared to women alone are being actively conducted. In this paper, the evidence of HPV vaccination for men will be reviewed through previous studies, and its validity and cost-effectiveness will be analyzed to bolster the clinical usefulness of HPV vaccination for men.

Keywords

References

  1. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res. 1976;36:794.
  2. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J. 1984;3:1151-1157. https://doi.org/10.1002/j.1460-2075.1984.tb01944.x
  3. Gissmann L, Boshart M, Durst M, Ikenberg H, Wagner D, zur Hausen H. Presence of human papillomavirus in genital tumors. J Invest Dermatol. 1984;83:26s-28s. https://doi.org/10.1111/1523-1747.ep12281143
  4. Syrjanen KJ, Pyrhonen S, Syrjanen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg. 1983;21:147-153. https://doi.org/10.1016/0007-117X(83)90060-4
  5. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24:2606-2611. https://doi.org/10.1200/JCO.2006.06.1291
  6. Villa A, Patton LL, Giuliano AR, Estrich CG, Pahlke SC, O'Brien KK, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews. J Am Dent Assoc. 2020;151:245-254.e224. https://doi.org/10.1016/j.adaj.2019.10.010
  7. Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012;131:1969-1982. https://doi.org/10.1002/ijc.27650
  8. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128-3137. https://doi.org/10.1200/JCO.2007.12.7662
  9. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24:5630-5636. https://doi.org/10.1200/JCO.2005.04.6136
  10. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420. https://doi.org/10.1093/jnci/djn025
  11. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, NguyenTan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35. https://doi.org/10.1056/NEJMoa0912217
  12. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ. 2013;346:f2032. https://doi.org/10.1136/bmj.f2032
  13. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. https://doi.org/10.1186/1741-7015-11-227
  14. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13: 89-99. https://doi.org/10.1016/S1470-2045(11)70286-8
  15. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630-632.
  16. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: A repeat cross-sectional study. Lancet Infect Dis. 2014;14:958-966. https://doi.org/10.1016/S1473-3099(14)70841-2
  17. Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vanska S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: A systematic review and meta-analysis of predictions from transmission-dynamic models. The Lancet Public Health. 2016;1:e8-e17. https://doi.org/10.1016/s2468-2667(16)30001-9
  18. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565-580. https://doi.org/10.1016/S1473-3099(14)71073-4
  19. Lehtinen M, Luostarinen T, Vanska S, Soderlund-Strand A, Eriksson T, Natunen K, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018;143:2299-2310. https://doi.org/10.1002/ijc.31618
  20. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr. Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364:401-411. https://doi.org/10.1056/NEJMoa0909537
  21. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144:449-468. https://doi.org/10.1017/S0950268815002198
  22. Nasman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287:134-152. https://doi.org/10.1111/joim.13010
  23. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199:1263-1269. https://doi.org/10.1086/597755
  24. Chaturvedi AK, Graubard BI, Broutian T, Pickard RK, Tong ZY, Xiao W, et al. NHANES 2009-2012 Findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res. 2015;75:2468-2477.
  25. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: The Manchester cohort. Br J Cancer. 2004;91:942-953. https://doi.org/10.1038/sj.bjc.6602049
  26. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, et al. The human papillomavirus infection in men study: Human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17:2036-2043. https://doi.org/10.1158/1055-9965.EPI-08-0151
  27. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174:927-936. https://doi.org/10.1093/infdis/174.5.927
  28. Edelstein ZR, Carter JJ, Garg R, Winer RL, Feng Q, Galloway DA, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis. 2011;204:209-216. https://doi.org/10.1093/infdis/jir242
  29. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19:261-267. https://doi.org/10.1128/CVI.05208-11
  30. Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123:2219-2229. https://doi.org/10.1002/cncr.30588
  31. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer. 2013;13:10. https://doi.org/10.1186/1471-2407-13-10
  32. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. https://doi.org/10.1136/bmj.b3884
  33. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011;204:372-376. https://doi.org/10.1093/infdis/jir285
  34. Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: A cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis. 2014;14:351. https://doi.org/10.1186/1471-2334-14-351
  35. Quinn MA. Cervical screening in the 21st century. J Med Assoc Thai. 2004;87 Suppl 3:S94-95.